| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 702 0 |
 SM ISO690:2012GUNTHER, Gunar, ALEXANDRU, Sofia, BARBUŢĂ, Raisa, CIOBANU, Ana, KRUDU, V.. Clinical management of multidrug-resistant tuberculosis in 16 european countries. In: American Journal of Respiratory and Critical Care Medicine, 2018, nr. 3(198), pp. 379-386. ISSN 1073-449X. DOI: https://doi.org/10.1164/rccm.201710-2141OC |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
 American Journal of Respiratory and Critical Care Medicine |
|
| Numărul 3(198) / 2018 / ISSN 1073-449X | |
|
|
| DOI:https://doi.org/10.1164/rccm.201710-2141OC | |
| Pag. 379-386 | |
| Rezumat | |
Rationale: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. Objectives: To document the management and treatment outcome in patients with MDR-TB in Europe. Methods: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients with MDR-TB in Europe. Treatment outcomes were compared by World Health Organization and alternative simplified definitions by the Tuberculosis Network European Trialsgroup (TBNET). Measurements and Main Results: A total of 380 patients with MDR-TB were recruited and followed up between 2010 and 2014 in 16 European countries. Patients in high-incidence countries compared with low-incidence countries were treated more frequently with standardized regimen (83.2% vs. 9.9%), had delayed treatment initiation (median, 111 vs. 28 d), developed more additional drug resistance (23% vs. 5.8%), and had increased mortality (9.4% vs. 1.9%). Only 20.1% of patients using pyrazinamide had proven susceptibility to the drug. Applying World Health Organization outcome definitions, frequency of cure (38.7% vs. 9.7%) was higher in high-incidence countries. Simplified outcome definitions that include 1 year of follow-up after the end of treatment showed similar frequency of relapse-free cure in low- (58.3%), intermediate- (55.8%), and high-incidence (57.1%) countries, but highest frequency of failure in high-incidence countries (24.1% vs. 14.6%). Conclusions: Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected by World Health Organization outcome definitions. |
|
| Cuvinte-cheie Extensively drug-resistant TB, management, MDR-TB, Outcome definitions, TBNET |
|
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Gunther, G.</dc:creator> <dc:creator>Alexandru, S.</dc:creator> <dc:creator>Barbuţă, R.</dc:creator> <dc:creator>Ciobanu, A.G.</dc:creator> <dc:creator>Crudu, V.N.</dc:creator> <dc:date>2018-08-01</dc:date> <dc:description xml:lang='en'><p>Rationale: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. Objectives: To document the management and treatment outcome in patients with MDR-TB in Europe. Methods: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients with MDR-TB in Europe. Treatment outcomes were compared by World Health Organization and alternative simplified definitions by the Tuberculosis Network European Trialsgroup (TBNET). Measurements and Main Results: A total of 380 patients with MDR-TB were recruited and followed up between 2010 and 2014 in 16 European countries. Patients in high-incidence countries compared with low-incidence countries were treated more frequently with standardized regimen (83.2% vs. 9.9%), had delayed treatment initiation (median, 111 vs. 28 d), developed more additional drug resistance (23% vs. 5.8%), and had increased mortality (9.4% vs. 1.9%). Only 20.1% of patients using pyrazinamide had proven susceptibility to the drug. Applying World Health Organization outcome definitions, frequency of cure (38.7% vs. 9.7%) was higher in high-incidence countries. Simplified outcome definitions that include 1 year of follow-up after the end of treatment showed similar frequency of relapse-free cure in low- (58.3%), intermediate- (55.8%), and high-incidence (57.1%) countries, but highest frequency of failure in high-incidence countries (24.1% vs. 14.6%). Conclusions: Conventional standard MDR-TB treatment regimens resulted in a higher frequency of failure compared with individualized treatments. Overall, cure from MDR-TB is substantially more frequent than previously anticipated, and poorly reflected by World Health Organization outcome definitions.</p></dc:description> <dc:identifier>10.1164/rccm.201710-2141OC</dc:identifier> <dc:source>American Journal of Respiratory and Critical Care Medicine 198 (3) 379-386</dc:source> <dc:subject>Extensively drug-resistant TB</dc:subject> <dc:subject>management</dc:subject> <dc:subject>MDR-TB</dc:subject> <dc:subject>Outcome definitions</dc:subject> <dc:subject>TBNET</dc:subject> <dc:title>Clinical management of multidrug-resistant tuberculosis in 16 european countries</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>
|
|
|
